CD22
Siglec 2
CD22 (Siglec 2) is a 135-kDa B-cell restricted antigen, and is an inhibitory coreceptor of the B-cell receptor (BCR). The extracellular portion of CD22 comprises seven immunoglobulin domains, and is responsible for binding α2,6Sia ligands. Interaction with these ligands in cis (on the B-cell surface) regulates the association of CD22 with the BCR and thereby modulates the inhibitory function of CD22. Interaction of CD22 to ligands in trans (on the surface of other cells) can regulate both B-cell migration as well as the BCR signaling threshold.
CD22 can also recruit the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits BCR-induced Ca2+ signaling on normal B cells. CD22 is critical in maintaining a baseline level of B-cell inhibition and homeostasis in humoral immunity. CD22 is a target molecule in dysregulated B cells that cause autoimmune diseases and blood cancers[1][2].
CD22 can also recruit the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits BCR-induced Ca2+ signaling on normal B cells. CD22 is critical in maintaining a baseline level of B-cell inhibition and homeostasis in humoral immunity. CD22 is a target molecule in dysregulated B cells that cause autoimmune diseases and blood cancers[1][2].
All Product Categories
-
CD22 Related Products (17)
Related Products (17)
-
Antibodies (17)
- 1
-
Inotuzumab
0 ImagesCat. No.: HY-P99264CAS No.: 1660159-36-3Synonyms: Humanized Anti-CD22 Recombinant AntibodyInotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.
-
Epratuzumab
0 ImagesSynonyms: Antibody hLL 2; AMG-412
-
Moxetumomab
0 ImagesMoxetumomab is a CD22-targeting monoclonal antibody that forms the component of Moxetumomab Pasudotox, a recombinant CD22-targeting immunotoxin. Moxetumomab binds to CD22 on malignant B cells and delivers the PE38 toxin domain to tumor cells. Moxetumomab can be used in research on relapsed or refractory hairy cell leukemia.
-
Suciraslimab
0 ImagesCat. No.: HY-P990781CAS No.: 2415439-63-1Synonyms: SM03Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).
-
Pinatuzumab
0 ImagesCat. No.: HY-P99230CAS No.: 1639820-81-7Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
-
Inotuzumab ozogamicin (solution)
0 ImagesCat. No.: HY-P9959ACAS No.: 635715-01-4Synonyms: CMC-544 (solution); PF-5208773 (solution); WAY-207294 (solution)Inotuzumab ozogamicin solution (CMC-544 solution) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin solution and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin solution has demonstrated efficacy against CD22+ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin solution can be used in the research of acute lymphoblastic leukemia.
-
6'-BPANeuGc
0 ImagesCat. No.: HY-185659CAS No.: 1596134-78-96'-BPANeuGc is a CD22-targeting ligand. 6'-BPANeuGc suppresses BCR activation, recruits CD22 to B cell immunological synapses, initiates inhibitory signals, induces B cell apoptosis. 6'-BPANeuGc inhibits calcium flux, and inhibits Akt and Erk activation. 6'-BPANeuGc can be used for research on immune system diseases.
-
TRPH-222 Antibody
0 ImagesCat. No.: HY-P991906Synonyms: CD22-4AP Antibody; CAT-02-106 AntibodyTRPH-222 Antibody (CD22-4AP Antibody) is an anti-human CD22 antibody site-specifically modified at one site per heavy chain to express formylglycine (FG), allowing site-specific conjugation of a maytansinoid payload, a protease-insensitive spacer, and a functional group for coupling to an aldehyde on antibody FG residues. TRPH-222 Antibody can generate antibody drug conjugate (ADC) (TRPH-222) with an ADC payload and a linker. TRPH-222 Antibody can be used for the study of NHL (non-Hodgkin's lymphoma).
-
Rezetamig
0 ImagesCat. No.: HY-P990759CAS No.: 2795115-07-8Synonyms: JNJ-75348780
-
Pinatuzumab vedotin
0 ImagesCat. No.: HY-141602CAS No.: 1313706-14-7Synonyms: anti-CD22-vc-MMAE; DCDT2980SPinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities.
-
Inotuzumab ozogamicin
0 ImagesSynonyms: CMC-544; PF-5208773; WAY-207294Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22+ B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia.
-
Anti-Mouse CD22 Antibody (Cy34.1)
0 ImagesCat. No.: HY-P990283Purity: 99%Anti-Mouse CD22 Antibody (Cy34.1) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to mouse CD22. Anti-Mouse CD22 Antibody (Cy34.1) can deplete CD22 cells and B cells. Anti-Mouse CD22 Antibody (Cy34.1) can promote microglial phagocytosis. Anti-Mouse CD22 Antibody (Cy34.1) can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease (AD) and neuromyelitis.
-
Mozistobart
0 ImagesSynonyms: AB-125
-
RFB4
0 ImagesCat. No.: HY-P991550CAS No.: 505393-48-6RFB4 is an anti-CD22 monoclonal antibody. RFB4 can be fused with Pseudomonas aeruginosa exotoxin (PE38) via disulfide bonds to construct recombinant immunotoxins, such as RFB4 (dsFv)-PE38. RFB4 is applicable to the research of cancers including lymphoma.
-
Inotuzumab (powder)
0 ImagesCat. No.: HY-P99264ACAS No.: 1660159-36-3Synonyms: Humanized Anti-CD22 Recombinant Antibody (powder)Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) (powder) is a humanized IgG4κ antibody that targets human CD22. Inotuzumab (powder) can be linked to a toxic agent Ozogamicin as an antibody-drug conjugate (ADC), Inotuzumab ozogamicin (HY-P9959). Inotuzumab (powder) can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma.
-
GSC-718
0 ImagesCat. No.: HY-171172CAS No.: 2493080-16-1
- 1
